natgillin/translations-raw huggingface dataset:
Frequency estimate: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from available data). 
Pogostnosti so določene kot: zelo pogosto (≥1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Driving and using machines Pemetrexed Hospira may make you feel tired. 
Vpliv na sposobnost upravljanja vozil in strojev Pemetreksed Hospira lahko povzroči, da se boste počutili utrujene.
Instructions for use, handling and disposal 
Navodila za uporabo, ravnanje z zdravilom in odstranjevanje
For intravenous use 
Za intravensko uporabo
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C. 
Če zdravila, pripravljenega za uporabo, ne uporabimo takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik, in naj bi ne presegali 24 ur pri 2 do 8 °C.
There are no data from the use of pemetrexed in pregnant women; but pemetrexed, like other antimetabolites, is suspected to cause serious birth defects when administered during pregnancy. 
Podatkov o uporabi pemetrekseda pri nosečnicah ni, a za pemetreksed, kot za druge antimetabolite, sumimo, da povzroča resne prirojene okvare, če ga dajemo med nosečnostjo.
Pemetrexed Hospira can have a minor or moderate influence on ability to drive and use machines. 
Zdravilo Pemetreksed Hospira ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Hospira. 
Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Pemetreksed Hospira.
This medicine is for single use only; any unused solution must be disposed of in accordance with local requirements. 
To zdravilo je namenjeno samo enkratni uporabi, morebitno neporabljeno raztopino je treba odstraniti v skladu z lokalnim predpisom.
Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for Pemetrexed Hospira used as a single agent or in combination with cisplatin. 
Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za zdravilo Pemetreksed Hospira, če jo uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
When using Pemetrexed Hospira in combination with cisplatin: 
Kadar uporabljamo Pemetreksed Hospira v kombinaciji s cisplatinom:
If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed Hospira. 
Če se vam okrog pljuč nabira tekočina, se bo zdravnik morda odločil tekočino pred dajanjem zdravila Pemetreksed Hospira odstraniti.
• Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection (since you might have fewer white blood cells than normal which is very common). 
• Povišana telesna temperatura ali okužba (pogosto): če se pojavi temperatura 38 ºC ali višja, znojenje ali drugi znaki okužbe (ker imate lahko manj belih krvničk kot normalno, kar je zelo pogosto).
A significant increase in the incidence of possibly study-drug-related Grade 3/4 neutropenia was observed with longer exposure to pemetrexed (≤6 cycles: 3.3%, >6 cycles: 6.4%: p=0.046). 
Znatno povečanje pojavnosti nevtropenije stopnje 3/4, ki je lahko povezano s preučevanim zdravilom, so opazili pri dolgotrajnejši izpostavljenosti pemetreksedu (≤ 6 ciklov: 3,3 %, > 6 ciklov: 6,4 %: p=0,046).
If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Pemetrexed Hospira. 
Če ste bili nedavno cepljeni, prosimo, povejte to zdravniku saj lahko to ob jemanju zdravila Pemetreksed Hospira povzroča škodljive učinke.
Treatment with Pemetrexed Hospira should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed. 
Zdravljenje z zdravilom Pemetreksed Hospira moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
Pemetrexed Hospira is a medicine used in the treatment of cancer. 
Pemetreksed Hospira je zdravilo, ki ga uporabljamo pri zdravljenju raka.
Hospira UK Limited 
Izdelovalec Hospira UK Limited Horizon
The dose of Pemetrexed Hospira is 500 milligrams for every square metre of your body's surface area. 
Odmerek zdravila Pemetreksed Hospira je 500 miligramov za vsak kvadratni meter površine vašega telesa.
What you need to know before you use Pemetrexed Hospira 
Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Hospira
What Pemetrexed Hospira is and what it is used for 
Kaj je zdravilo Pemetreksed Hospira in za kaj ga uporabljamo
Corticosteroids: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Pemetrexed Hospira treatment. 
Kortikosteroidi: zdravnik vam bo predpisal tablete steroidov (ustrezno 4 miligramom deksametazona dvakrat dnevno), ki jih boste morali jemati dan pred zdravljenjem z zdravilom Pemetreksed Hospira, na dan zdravljenja in na dan po zdravljenju z zdravilom Pemetreksed Hospira.
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen). 
Druga zdravila in zdravilo Pemetreksed Hospira Prosimo, povejte zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo ibuprofen).
Refer to section 2 “Pemetrexed Hospira contains sodium”. 
Glejte poglavje 2 “Pemetreksed Hospira vsebuje natrij”.
When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature (2°C to 8°C). 
Po pripravi po navodilih so kemijsko in fizikalno obstojnost za uporabo rekonstituiranih raztopin pemetrekseda in raztopin pemetrekseda za infundiranje pokazali za 24 ur v hladilniku (2°C do 8°C).
If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), Pemetrexed Hospira should be withheld until resolution to less than or equal to the patient's pre-therapy value. 
Če se pri bolnikih razvijejo nehematološke toksičnosti ≥ stopnje 3 (z izjemo nevrološke toksičnosti), moramo dajanje zdravila Pemetreksed Hospira prekiniti, dokler se vrednosti ne povrnejo na manjše ali enake, kot jih je imel bolnik pred zdravljenjem.
Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver) 
Imunsko pogojena hemolitična anemija (propad rdečih krvnih celic, ki ga povzročijo protiteles) Hepatitis (vnetje jeter)
You will always receive Pemetrexed Hospira by infusion into one of your veins. 
Zdravilo Pemetreksed Hospira boste vedno prejeli v obliki infuzije v veno.
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Pemetrexed Hospira. 
Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Pemetreksed Hospira.
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Hospira has finished. 
Cisplatin tudi dajemo v obliki infuzije v veno, približno 30 minut po zaključku infuzije zdravila Pemetreksed Hospira.
• If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may indicate a blood clot in the blood vessels of the lungs). 
• Če doživite nenadno težko dihanje, močno bolečino v prsih ali kašelj s krvavim izmečkom (redko) (lahko kaže na krvni strdek v krvnih žilah v pljučih).
To be taken into consideration by patients on a controlled sodium diet. 
Ta podatek je treba upoštevati pri bolnikih, ki so na dieti z nadzorovanim vnosom natrija.
A phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fluid demonstrated no difference in pemetrexed dose normalised plasma concentrations or clearance compared to patients without third space fluid collections. 
V študiji pemetrekseda so v fazi II pri 31 bolnikih s solidnim tumorjem in stabilno tekočino tretjega prostora pokazali, da ni razlike med normalno koncentracijo v plazmi ali očistkom, doseženo glede na odmerek pemetrekseda, v primerjavi z bolniki brez zaloge tekočine tretjega prostora.
Pemetrexed Hospira must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy. 
Zdravilo Pemetreksed Hospira smemo dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije za zdravljenje raka.
Pemetrexed Hospira can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy. 
Zdravnik vam lahko predpiše zdravilo Pemetreksed Hospira, če imate pljučni rak v napredovalem stadiju in če se vaša bolezen odziva na zdravljenje oz. če po začetni kemoterapiji ostaja večinoma nespremenjena.
However, patients with hepatic impairment, such as bilirubin > 1.5-times the upper limit of normal and/or aminotransferase > 3.0-times the upper limit of normal (hepatic metastases absent) or > 5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied. 
Vendar pa bolnikov z okvarjenim delovanjem jeter, ki se kaže kot bilirubin > 1,5-kratnik zgornje meje normalnih vrednosti in/ali aminotransferaza > 3,0-kratnik zgornje meje normalnih vrednosti (brez zasevkov v jetrih) ali > 5,0-kratnik zgornje meje normalnih vrednosti (z zasevki v jetrih), niso posebej preučevali.
Limited clinical data from a separate randomised, Phase-3, controlled trial, suggest that efficacy data (overall survival, progression-free survival) for pemetrexed are similar between patients previously pre-treated with docetaxel (N = 41) and patients who did not receive previous docetaxel treatment (N = 540). 
Omejeni klinični podatki iz ločeno randomiziranih, kontroliranih preskušanj faze 3, nakazujejo, da so podatki o učinkovitosti (skupno preživetje, preživetje brez napredovanja) za pemetreksed podobni med bolniki, ki so bili predhodno zdravljeni z doksatakselom (n = 41) in bolniki, ki niso prejeli predhodnega zdravljenja z doksatakselom (n = 540).
Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1,000 micrograms) that you must take once a day while you are taking Pemetrexed Hospira. 
Dopolnjevanje vitaminov: zdravnik vam bo predpisal peroralno folno kislino (vitamin) ali multivitaminski pripravek, ki jo vsebuje (350 do 1.000 mikrogramov), ki ga boste morali med prejemanjem zdravila Pemetreksed Hospira jemati enkrat dnevno.
Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson syndrome or toxic epidermal necrolysis). 
Obvestite zdravnika, če se pojavijo hud izpuščaj, srbenje ali mehurčki (StevensJohnsonov sindrom ali toksična epidermalna nekroliza).
Pemetrexed Hospira is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer. 
Pemetreksed Hospira se daje tudi v kombinaciji s cisplatinom, za začetno zdravljenje bolnikov z napredovalim stadijem pljučnega raka.
A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Hospira powder with 9 mg/ml (0.9 %) sodium chloride solution for injection before it is given to you. 
Bolnišnični farmacevt, medicinska sestra ali zdravnik bo prašek Pemetreksed Hospira, preden ga boste prejeli, zmešal z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
You will also receive an injection of vitamin B12 (1,000 micrograms) in the week before administration of Pemetrexed Hospira and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed Hospira treatment). 
V tednu pred dajanjem zdravila Pemetreksed Hospira boste prejeli tudi injekcijo vitamina B12 (1.000 mikrogramov), nato pa še približno na vsakih 9 tednov (ustrezno 3 ciklusom zdravljenja z zdravilom Pemetreksed Hospira).
Pemetrexed Hospira is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used. 
Pemetreksed Hospira je namenjen tudi zdravljenju bolnikov z napredovalim stadijem pljučnega raka, katerih bolezen se širi po tem, ko je bila že uporabljena druga začetna kemoterapija.
treatment until disease progression. 
Bolniki so prejeli vzdrževalno zdravljenje do napredovanja bolezni.
This should be taken into consideration if you are on a strictly controlled sodium diet. 
Ta podatek upoštevajte, če ste na dieti z nadzorovanim vnosom natrija.
Concomitant administration of nephrotoxic drugs (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin) could potentially result in delayed clearance of pemetrexed. 
Sočasno dajanje nefrotoksičnih zdravil (denimo, aminoglikozidov, diuretikov zanke, spojin platine, ciklosporina) lahko potencialno povzroči zakasnjeni očistek pemetrekseda.
If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pemetrexed Hospira. 
Če ste imeli ali če boste imeli zdravljenje z obsevanjem, prosimo, povejte to zdravniku, saj ob jemanju zdravila Pemetreksed Hospira.lahko pride do zgodnje ali pozne reakcije na obsevanje.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and cisplatin is documented in Table 3. 
Priporočene prilagoditve odmerkov zdravila Pemetreksed Hospira in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
• If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have fewer platelets than normal which is very common). 
• Če vam krvavijo dlesni, krvavite iz nosu ali ustne votline, ali se pojavi kakršnakoli krvavitev, ki se noče ustaviti, rdečkasto ali rožnato obarvan urin, nepričakovane podplutbe (ker imate lahko manj trombocitov, kot je normalno, kar je zelo pogosto).
Chemical and physical in-use stability of reconstituted and infusion solutions of Pemetrexed Hospira powder for concentrate for solution for infusion has been demonstrated for up to 24 hours after reconstitution of the original vial when stored below 25°C. 
Rekonstituirane raztopine in raztopine za infundiranje Kemijsko in fizikalno obstojnost za uporabo rekonstituiranih raztopin in raztopin za infundiranje zdravila Pemetreksed Hospira prašek za koncentrat za raztopino za infundiranje so pokazali za 24 ur v hladilniku, po pripravi originalne viale, shranjene pri temperaturi do 25 °C.
Efficacy of pemetrexed vs. docetaxel in NSCLC - ITT population Pemetrexed 
Učinkovitost pemetrekseda v primerjavi z docetakselom pri NSCLC - Populacija NZ
Pemetrexed Hospira is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy. 
Zdravilo Pemetreksed Hospira dajemo v kombinaciji s cisplatinom, drugim zdravilom proti raku, za zdravljenje malignega plevralnega mezotelioma, vrste raka, ki prizadene vrhnjo plast pljuč, bolnikom, ki pred tem še niso prejemali kemoterapije.
Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication. 
Pemetreksed je večtarčno protirakavo antifolatno zdravilo, ki deluje s porušenjem ključnih presnovnih procesov, odvisnih od folata, ki so nujni za podvajanje celic.
Pemetrexed Hospira 100 mg contains less than 1 mmol (23 mg) of sodium i.e. essentially ‘sodium free'. 
Pemetreksed Hospira 100 mg vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni "brez natrija".
For instructions on reconstitution and dilution of Pemetrexed Hospira before administration, see section 6.6 
Za informacije o rekonstituciji in redčenju zdravila Pemetreksed Hospira pred uporabo glejte poglavje 6.6.
The other ingredients are mannitol (E421), hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH adjustment). 
Pomožne snovi so manitol (E421), klorovodikova kislina (za uravanavanje pH) in natrijev hidroksid (za uravnavanje pH).
Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis. 
Redkeje opaženi učinki so Stevens- Johnsonov sindrom in toksična epidermalna nekroliza.
Randomised and treated patients Fully supplemented patients 
Randomizirani in zdravljeni bolniki
Gemcitabine + Cisplatin 
Prednost pvrednost pemetreksed + cisplatin gemcitabin + cisplatin
Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chlorideand polyolefin- lined administration sets and infusion bags. 
Raztopine pemetrekseda za infundiranje, pripravljene, kot je navedeno zgoraj, so skladne s seti za dajanje in infuzijskimi vrečkami iz polivinilklorida in prevlečenimi s poliolefinom.
Pemetrexed*** (N = 800) 
Dogodek** Pemetreksed*** (N = 800)
Further dilution by a healthcare provider is required prior to administration. 
Pred dajanjem mora zdravstveni delavec raztopino še dodatno razredčiti.
Dose of Pemetrexed Hospira (mg/m2) 
Odmerek zdravila Pemetreksed Hospira (mg/m
You must contact your doctor immediately if you notice any of the following: 
Če opazite katerega od spodaj naštetih učinkov, morate nemudoma poklicati zdravnika:
You must take at least 5 doses during the seven days before the first dose of Pemetrexed Hospira. 
V sedmih dneh pred prvim odmerkom zdravilom Pemetreksed Hospira morate vzeti vsaj 5 odmerkov.
Each pack contains one vial of 100 mg, 500 mg or 1,000 mg pemetrexed as (pemetrexed disodium hemipentahydrate). 
Vsako pakiranje vsebuje eno vialo s 100 mg, 500 mg ali 1.000 mg pemetrekseda (v obliki dinatrijevega pemetrekseda hemipentahidrata).
Pemetrexed Hospira should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. 
Zdravilo Pemetreksed Hospira se daje kot 10-minutna intravenska infuzija prvi dan vsakega 21dnevnega ciklusa.
Leucocytes decreased 53.0 Haemoglobin decreased 26.2 Platelets decreased 
Znižani levkociti 53,0 Znižan hemoglobin Znižani trombociti
Not known (frequency cannot be estimated from the available data) 
Neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) Otekanje spodnjih okončin z bolečino in pordelostjo Povečano izločanje urina
Gemcitabine/Cisplatin (N = 830) 
Gemcitabin/cisplatin (N = 830)
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (N = 399, 9.3 versus 8.0 months, adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (N =172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018). 
Analiza vpliva histologije NSCLC glede učinka zdravljenja na skupno preživetje je bila prednostna za pemetreksed proti docetakselu pri tistih, ki nimajo pretežno luskaste histologije (n = 399, 9,3 proti 8,0 mesecev, prilagojen RT = 0,78; 95 % IZ = 0,61-1,00, p = 0,047) in je bila prednostna za docetaksel za luskasto celično histologijo karcinoma (n = 172, 6,2 proti 7,4 mesecev, prilagojen RT = 1,56; 95 % IZ = 1,082,26, p = 0,018).
• HR (95% CI) 
• RT (95% IZ)
Dose modification table for Pemetrexed Hospira (as single agent or in combination) and cisplatin - Non-haematologic toxicities a, b 
Preglednica 2 - Preglednica za prilagajanje odmerkov zdravila Pemetreksed Hospira (kot edine učinkovine ali v kombinaciji) in cisplatina - Nehematološke toksičnosti a, b
Excipients: mannitol, hydrochloric acid concentrated, sodium hydroxide (see package leaflet for further information) 
Pomožne snovi: manitol, koncentrirana klorovodikova kislina, natrijev hidroksid (Opozorila so navedena v navodilu za uporabo).
A multi-centre, randomised, open-label, Phase-3 study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed plus cisplatin (Intent-To-Treat [ITT] population N = 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT N = 863) in overall survival (adjusted hazard ratio (HR) 0.94; 95% CI= 0.84-1.05). 
Multicentrična, randomizirana, odprta študija faze 3 pemetrekseda skupaj s cisplatinom proti gemcitabinu skupaj s cisplatinom pri bolnikih, ki v preteklosti še niso prejemali kemoterapije, z lokalno napredovalim ali metastatskim (stopnja IIIb ali IV) nedrobnoceličnim karcinomom pljuč (NSCLC), je pokazala, da je pemetreksed skupaj s cisplatinom (Populacija z namenom zdraviti, [NZ] populacija N = 862) dosegla prvotno končno točko in pokazala podobno klinično učinkovitost, kot gemcitabin skupaj s cisplatinom (NZ N = 863) v skupnem preživetju (prilagojeno razmerje tveganja 0,94; 95 % IZ = 0,84-1,05).
Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma 
Učinkovitost pemetrekseda skupaj s cisplatinom v primerjavi s cisplatinom pri malignem plevralnem mezoteliomu
How to use Pemetrexed Hospira 
Kako uporabljati zdravilo Pemetreksed Hospira
Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95% CI=0.64-0.96, p=0.0195). 
Po indukcijskem zdravljenju s pemetreksedom skupaj s cisplatinom (4 cikli) je bilo zdravljenje s pemetreksedom statistično boljše od placeba glede skupnega preživetja (mediana 13,9 mesecev v primerjavi z 11,0 meseci, razmerje tveganja = 0,78, 95 % IZ=0,64-0,96, p=0,0195).
Pemetrexed Hospira contains sodium 
Pemetreksed Hospira vsebuje natrij
The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes. 
Ustrezno prostornino rekonstituirane raztopine pemetrekseda moramo še nadalje redčiti do 100 ml z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje brez konzervansa; damo jo kot intravensko infuzijo, ki teče 10 minut.
Type I glass vial with rubber stopper containing 100 mg, 500 mg or 1,000 mg of pemetrexed (as pemetrexed disodium hemipentahydrate). 
Steklena viala tipa I z gumijasto zaporko, ki vsebuje 100 mg, 500 mg ali 1.000 mg pemetrekseda ( v obliki dinatrijevega pemetrekseda hemipentahidrata).
Dose modification table for Pemetrexed Hospira (as single agent or in combination) and cisplatin - Neurotoxicity 
Preglednica 3 - Preglednica za prilagajanje odmerkov zdravila Pemetreksed Hospira (kot edine učinkovine ali v kombinaciji) in cisplatina - Nevrotoksičnost
75% of previous dose (both Pemetrexed 
75 % predhodnega odmerka (obeh - zdravila Pemetreksed Hospira in cisplatina)